Free Republic

Recently, a tiny group of people with rectal cancer saw their disease vanish after experimental treatment. Now, in another breakthrough, a new compound synthesized by Dr. Jung-Mo Ahn, a University of Texas at Dallas researcher, has been found to kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, leaving healthy cells unscathed. He exploited a weakness in cells that were hitherto not targeted by the other drugs. The study, which was carried out in isolated cells, both in human cancer tissue and in human cancers grown in mice, was published in the journal Nature Cancer. Only a few...

A new vaccine developed using the same technology as the BioNTech-Pfizer Covid jab has raised hopes of a cure for pancreatic cancer. In early trial results of the jab - which uses mRNA theory and is designed to prevent tumours from returning after surgery - half of the patients given a vaccine remained cancer free 18 months later. The inoculation, developed by scientists working with pharmaceutical firm BioNTech and US company Genentech, has raised hopes of finally finding a cure for the deadliest common cancer which claims the lives of 90 per cent of patients within two years of diagnosis....

A study has found that a drug named Dostarlimab has helped treat rectal cancer. This has been described as a "first time in history"kind of result in cancer treatment with the disease simply vanishing in patients after the experimental treatment. Here are 10 things to know about Dostarlimab, the drug that cured cancer during trial:1. The clinical trial comprised a group of 18 patients. All of them were battling rectal cancer at the Memorial Sloan Kettering Cancer Center in Manhattan, US. 2. In all patients, rectal cancer was locally advanced. This means the tumours had spread within the rectum and...

A combination of chemotherapy with an immunotherapy meant to unleash the anticancer capacity of the immune system was effective against one of the hardest targets in cancer care, pancreatic cancer, in a national, randomized clinical trial. The researchers found that in 34 patients with advanced pancreatic cancer randomized to receive the immunotherapy nivolumab with two chemotherapy drugs, nab-paclitaxel and gemcitabine, had a one-year survival rate of 57.7 percent, significantly greater than the historical average of 35 percent with chemotherapy alone. The findings also included the identification of immune system biomarkers associated with better outcomes. A ray of hope has come...

Patients with a particular kind of cancer and a particular kind of mutation received a new therapy called dostarlimab and had results not seen in a cancer trial before. To be sure, the trial — led by doctors at Memorial Sloan Kettering and backed by drug maker GlaxoSmithKline — has only completed treatment of 12 patients, with a specific cancer in its early stages and with a rare mutation as well. But the results, reported Sunday in the New England Journal of Medicine and the New York Times, were still striking enough to prompt multiple physicians to tell the paper...

Acancer treatment has shown astounding results in a small clinical trial. All of the treated patients, who had a specific form of mid-stage rectal cancer, have since experienced complete remission. Though the findings are based on a sample size of just 18 people, they could hold important implications for treating these particular cancers. The results of the Phase II trial were published over the weekend in the New England Journal of Medicine . The study involved researchers at the Memorial Sloan Kettering Cancer Center as well as Yale University, and it was sponsored by the pharmaceutical company GlaxoSmithKline. The trial...

A new study published in The New England Journal of Medicine has shown that all 18 rectal cancer patients participating in an experimental drug trial went into remission following a six-month treatment. The study, the Journal reported, was spearheaded by doctors at Memorial Sloan Kettering. Drug maker GlaxoSmithKline also backed the research. According to the study, 18 cancer patients who were given the experimental immunotherapy drug dostarlimab every three weeks for six months ended up in remission by the end of the trial. A portion of the study read, “We initiated a prospective phase 2 study in which single-agent dostarlimab,...

A protein that destroys hard to treat cancers has been discovered by scientists - offering hope of effective new treatments. Experiments on mice and human tissue found it is effective against the most aggressive tumors. They include those of the breast, pancreas, ovaries and brain. The compound, known as ERX-41, leaves healthy tissue unscathed. It is one of the most promising breakthroughs to date - offering hope of a "one size fits all"' pill that was once thought impossible. Results were so encouraging clinical trials are expected to begin in the next few months. Lead author Professor Ratna Vadlamudi, of...

Low doses of freeze-dried grape powder inhibit genes linked to the development of sporadic colorectal cancer, University of California, Irvine cancer researchers found. The study suggests that a diet rich in grapes may help prevent the third most common form of cancer, one that kills more than a half a million people worldwide each year. Around 7 percent of all Americans develop colon cancer during their lifetimes. Led by Dr. Randall Holcombe, director of clinical research at the Chao Family Comprehensive Cancer Center at UC Irvine, the study followed up on previous in vitro studies showing that resveratrol, a...

In what appears to be a very promising breakthrough for the treatment of rectal cancer, a small drug trial conducted in the US found every patient treated in the experiment had their cancer successfully go into remission. The medication given, called dostarlimab and sold under the brand name Jemperli, is an immunotherapy drug used in the treatment of endometrial cancer, but this was the first clinical investigation of whether it was also effective against rectal cancer tumors. The early results reported so far suggest it is surprisingly effective, with the research team saying the successful cancer remission seen in every...